Drug Profile
Research programme: immunomodulatory therapeutics - Aldeyra Therapeutics and Janssen Research & Development
Alternative Names: Immune-modulating drugs - Aldeyra Therapeutics and Janssen Research & DevelopmentLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Aldeyra Therapeutics; Janssen Research & Development
- Class Anti-inflammatories
- Mechanism of Action Aldehyde modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Inflammation in USA
- 27 Feb 2018 Aldeyra Therapeutics and Janssen Research & Development enter into an agreement to develop immune-modulating drugs for Inflammation
- 27 Feb 2018 Early research in Inflammation in USA (unspecified route)